Loading
A phase 2 trial of Pentostatin, Rituximab and Bendamustine in Hairy cell leukaemia, run by National Cancer Institute (NCI), active and no longer recruiting.
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia is a phase 2 interventional study registered as NCT01059786 by National Cancer Institute (NCI), with 69 participants planned, started 2010-07-01 and due to reach its primary completion in 2022-12-15. Interventions recorded: Pentostatin, Rituximab, Bendamustine, Acetaminophen, Diphenhydramine, Epinephrine, Antihistamines, Corticosteroids, Bronchodilators, Intravenous (IV) Saline. Conditions recorded: Hairy Cell Leukemia.
Linked to the drug Pentostatin because the registry names it among its interventions and Hairy cell leukaemia among its conditions. Registry record only: no result has been read by an editor.
Shares Pentostatin, Rituximab and the tag pipeline.
Shares Pentostatin and the tag pipeline.
Shares Bendamustine, Rituximab and the tag pipeline.
Shares Bendamustine, Rituximab and the tag pipeline.
Shares Bendamustine, Rituximab and the tag pipeline.
Shares Bendamustine, Rituximab and the tag pipeline.
Shares Bendamustine, Rituximab and the tag pipeline.
Shares Bendamustine, Rituximab and the tag pipeline.